Genetic testing for at least 2 HLA variants to predict the patient’s risk of a severe drug hypersensitivity reaction to carbamazepine or oxcarbazepine, if the service is conducted before or during the initiation of treatment with carbamazepine or oxcarbazepine Applicable once per lifetime
Genetic testing for at least 2 HLA variants to predict the patient’s risk of a severe drug hypersensitivity reaction to carbamazepine or oxcarbazepine, if the service is conducted before or during the initiation of treatment with carbamazepine or oxcarbazepine Applicable once per lifetime
| Release | Change | Old | New |
|---|---|---|---|
| July 2026 | Listed | — | $139.0 |
Data sourced from Australian Government publications · Not an official government service